NCT06176768CompletedPhase 2
A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3972406 in Adults With Moderate-to-Severe Plaque Psoriasis
Source: ClinicalTrials.gov · Last updated 15 Oct 2025
Brief summary (registry, in English)
The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (actual)
- First submitted
- 11 Dec 2023
- Start date
- 6 Dec 2023
- Primary completion date
- 1 Apr 2025
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Psoriasis
- NCT number
- NCT06176768
- EU CT number
- 2023-504485-39-00
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 33
- From 6 Dec 2023 to the primary completion date, 1 Apr 2025
- 12 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have any other skin conditions, excluding plaque psoriasis
- Have a current or recent acute, active infection
- Have manifestations of other autoimmune diseases, such as systemic lupus erythematosus.
Other
- Are lactating or breastfeeding women
Who the study is looking for
- Have moderate-to-severe chronic plaque psoriasis for at least 6 months prior to baseline
- Have venous access sufficient to allow for blood sampling
- Are able to swallow oral medication
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (12)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| DermDox Centers for Dermatology Coordinator of this site? Confirm its status | Camp Hill | United States | Unknown status |
| Remington Davis, Inc. Coordinator of this site? Confirm its status | Columbus | United States | Unknown status |
| Driven Research Coordinator of this site? Confirm its status | Coral Gables | United States | Unknown status |
| Psoriasis Treatment Center of Central New Jersey Coordinator of this site? Confirm its status | East Windsor | United States | Unknown status |
| Schweiger Dermatology Group Coordinator of this site? Confirm its status | Hackensack | United States | Unknown status |
| Austin Institute for Clinical Research Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
| Center for Clinical Studies Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
| Metropolitan Dermatology - Clark Coordinator of this site? Confirm its status | Kenilworth | United States | Unknown status |
| Dermatology Research Associates Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
| Clinical Science Institute Coordinator of this site? Confirm its status | Santa Monica | United States | Unknown status |
| Accellacare - Winston-Salem Coordinator of this site? Confirm its status | Winston-Salem | United States | Unknown status |
| Conquest Research Coordinator of this site? Confirm its status | Winter Park | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.